New trends about the application and safety of specific cycloozygenase-2 inhibitors

Merck Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib) from the U.S. and worldwide market. Recently released data from controlled clinical trials showed that the specific cycloox-ygenase-2 (COX-2) inhibitors (celecoxib and valdecoxib) might be associated with an increased risk of serious cardiovascular events (including heart attack and stroke). The current demand were to revalue the specific COX-2 inhibitors and traditional nonsteroidal antiinflammatory drugs (NSAIDs) and to reconfirm the safety of these drugs. While the results of these studies were preliminary and conflicted with other study data on the same drugs, the Food and Drug Administration (FDA) and the State Food and Drug Administration (SFDA) is made the following interim recommendations: Physicians prescribing celecoxib or valdecoxib, should consider this emerging information when they weighted the benefits against risks for individual patients.